B Cells in Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 16-23

  Sarantopoulos, Stefanie ^a   Blazar, Bruce R ^b   Cutler, Corey ^c   Ritz, Jerome ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

B cell; Chronic graft versus host disease; Stem cell transplantation

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; B CELL ACTIVATING FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FOSTAMATINIB; IBRUTINIB; IMATINIB; IMMUNOGLOBULIN; KD 025; PREDNISONE; RHO KINASE INHIBITOR; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; B CELL ACTIVATING FACTOR RECEPTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TNFRSF13C PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LONG TERM CARE; LUNG FUNCTION TEST; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PHYSICIAN; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; ALLOTRANSPLANTATION; ANIMAL; CHRONIC DISEASE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; CHRONIC DISEASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MICE; RITUXIMAB; TRANSPLANTATION, HOMOLOGOUS;

EID: 84926638546     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.029     Document Type: Review

References (87)

1. Pidala J., Sarwal M., Roedder S., Lee S.J. Biologic markers of chronic GVHD. Bone Marrow Transplant 2014, 49:324-331.
2. Duarte R.F., Greinix H., Rabin B., et al. Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force. Bone Marrow Transplant 2014, 49:49-54.
3. Socie G., Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014, 124:374-384.
4. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
5. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
6. Srinivasan M., Flynn R., Price A., et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 2012, 119:1570-1580.
7. Kharfan-Dabaja M.A., Cutler C.S. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol 2011, 93:578-585.
8. Wardemann H., Yurasov S., Schaefer A., et al. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
9. Nemazee D. Does immunological tolerance explain the waste in the B-lymphocyte immune system? Experiment and theory. Ann N Y Acad Sci 1995, 764:397-401.
10. Goodnow C.C. Balancing immunity and tolerance: deleting and tuninglymphocyte repertoires. Proc Natl Acad Sci U S A 1996, 93:2264-2271.
11. Meffre E., Davis E., Schiff C., et al. Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol 2000, 1:207-213.
12. Yurasov S., Wardemann H., Hammersen J., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. JExp Med 2005, 201:703-711.
13. Cancro M.P. Peripheral B-cell maturation: the intersection of selection and homeostasis. Immunol Rev 2004, 197:89-101.
14. Thien M., Phan T.G., Gardam S., et al. Excess BAFF rescues self-reactive Bcells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
15. Lesley R., Xu Y., Kalled S.L., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
16. Tata P.V., Vincent B.G., Kuan P.F., et al. High-throughput immunoglobulin heavy chain variable region repertoire analysis of CD27+ B cell subsets from patients with chronic GVHD. Blood 2013, 122:2055. [ASH Annual Meeting Abstracts].
17. Patriarca F., Skert C., Sperotto A., et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006, 34:389-396.
18. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007, 110:237-241.
19. Kier P., Penner E., Bakos S., et al. Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant 1990, 6:93-96.
20. Cyster J.G., Hartley S.B., Goodnow C.C. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994, 371:389-395.
21. Jacobson C.A., Sun L., Kim H.T., et al. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:668-675.
22. Fedoriw Y., Samulski T.D., Deal A.M., et al. Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development. Biol Blood Marrow Transplant 2012, 18:968-973.
23. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
24. Storek J., Witherspoon R.P., Webb D., Storb R. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol 1996, 52:82-89.
25. Glauzy S., Soret J., Fournier I., et al. Impact of acute and chronic graft-versus-host disease on human B-cell generation and replication. Blood 2014, 124:2459-2462.
26. Le Huu D., Matsushita T., Jin G., et al. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. Blood 2013, 121:3274-3283.
27. Khoder A., Sarvaria A., Alsuliman A., et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood 2014, 124:2034-2045.
28. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Recovery of B-cell homeostasisafter rituximab in chronic graft-versus-host disease. Blood 2011, 117:2275-2283.
29. Allen J.L., Wooten J., Fore M., et al. Bcells from patients with chronic GVHD signal via the AKT-driven survival and metabolic fitness pathway. Biol Blood Marrow Transplant 2012, 18:S208. [BMT Tandem Meeting Abstracts].
30. Oliver P.M., Vass T., Kappler J., Marrack P. Loss of the proapoptotic protein, Bim, breaks B cell anergy. JExp Med 2006, 203:731-741.
31. Enders A., Bouillet P., Puthalakath H., et al. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. JExp Med 2003, 198:1119-1126.
32. Allen J.L., Fore M.S., Wooten J., et al. Bcells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 2012, 120:2529-2536.
33. Caro-Maldonado A., Wang R., Nichols A.G., et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. JImmunol 2014, 192:3626-3636.
34. Cancro M.P. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 2009, 9:657-661.
35. Patke A., Mecklenbrauker I., Erdjument-Bromage H., et al. BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. JExp Med 2006, 203:2551-2562.
36. Allen J.L., Tata P.V., Fore M.S., et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood 2014, 123:2108-2115.
37. Tan J.E., Wong S.C., Gan S.K., et al. The adaptor protein BLNK is required for b cell antigen receptor-induced activation of nuclear factor-kappa B and cell cycle entry and survival of B lymphocytes. JBiol Chem 2001, 276:20055-20063.
38. Fu L., Lin-Lee Y.C., Pham L.V., et al. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 2009, 113:4627-4636.
39. Tivol E., Komorowski R., Drobyski W.R. Emergent autoimmunity in graft-versus-host disease. Blood 2005, 105:4885-4891.
40. Young J.S., Wu T., Chen Y., et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. JImmunol 2012, 189:222-233.
41. Zhao D., Young J.S., Chen Y.H., et al. Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graft-versus-host disease. JImmunol 2011, 186:856-868.
42. Zorn E., Miklos D.B., Floyd B.H., et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. JExp Med 2004, 199:1133-1142.
43. Porcheray F., Miklos D.B., Floyd B.H., et al. Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation 2011, 92:359-365.
44. Biedermann B.C., Sahner S., Gregor M., et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002, 359:2078-2083.
45. von Bulow G.U., van Deursen J.M., Bram R.J. Regulation of the T-independent humoral response by TACI. Immunity 2001, 14:573-582.
46. Hon H., Oran A., Brocker T., Jacob J. Blymphocytes participate in cross-presentation of antigen following gene gun vaccination. JImmunol 2005, 174:5233-5242.
47. Tsoi M.S., Storb R., Jones E., et al. Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man. JImmunol 1978, 120:1485-1492.
48. Groh V., Li Y.Q., Cioca D., et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 2005, 102:6461-6466.
49. Kita H., Lian Z.X., Van de Water J., et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. JExp Med 2002, 195:113-123.
50. Rafiq K., Bergtold A., Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. JClin Invest 2002, 110:71-79.
51. Simpson N., Gatenby P.A., Wilson A., et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010, 62:234-244.
52. Weinstein J.S., Hernandez S.G., Craft J. Tcells that promote B-Cell maturation in systemic autoimmunity. Immunol Rev 2012, 247:160-171.
53. Flynn R., Du J., Veenstra R.G., et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood 2014, 123:3988-3998.
54. Treml L.S., Crowley J.E., Cancro M.P. BLyS receptor signatures resolve homeostatically independent compartments among naive and antigen-experienced B cells. Semin Immunol 2006, 18:297-304.
55. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 2006, 18:276-283.
56. Panoskaltsis-Mortari A., Tram K.V., Price A.P., et al. Anew murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med 2007, 176:713-723.
57. Cutler C., Kim H.T., Bindra B., et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013, 122:1510-1517.
58. Johnston H.F., Xu Y., Racine J.J., et al. Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects. Biol Blood Marrow Transplant 2014, 20:1089-1103.
59. Bunting K.L., Melnick A.M. New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. Curr Opin Immunol 2013, 25:339-346.
60. Floyd S.R., Pacold M.E., Huang Q., et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 2013, 498:246-250.
61. Cerchietti L.C., Yang S.N., Shaknovich R., et al. Apeptomimetic inhibitor of BCL6 with potent antilymphoma effects invitro and invivo. Blood 2009, 113:3397-3405.
62. Duy C., Yu J.J., Nahar R., et al. BCL6 is critical for the development of a diverse primary B cell repertoire. JExp Med 2010, 207:1209-1221.
63. Konze K.D., Ma A., Li F., et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol 2013, 8:1324-1334.
64. He S., Wang J., Kato K., et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood 2012, 119:1274-1282.
65. Filippakopoulos P., Qi J., Picaud S., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
66. Basso K., Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 2012, 247:172-183.
67. Ci W., Polo J.M., Cerchietti L., et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 2009, 113:5536-5548.
68. Boerma M., Fu Q., Wang J., et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008, 19:709-718.
69. Zanin-Zhorov A., Mo R., Scher J., et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells. Proc Natl Acad Sci U S A 2014, 10.1073/pnas.1414189111.
70. Berg L.J., Finkelstein L.D., Lucas J.A., Schwartzberg P.L. Tec family kinases in T lymphocyte development and function. Annu Rev Immunol 2005, 23:549-600.
71. Satterthwaite A.B., Witte O.N. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 2000, 175:120-127.
72. Chang B.Y., Huang M.M., Francesco M., et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011, 13:R115.
73. Herman S.E., Gordon A.L., Hertlein E., et al. Bruton tyrosine kinase representsa promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
74. Dubovsky J.A., Beckwith K.A., Natarajan G., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood 2013, 122:2539-2549.
75. Hamilton B.L., Parkman R. Acute and chronic graft-versus-host disease induced by minor histocompatibility antigens in mice. Transplantation 1983, 36:150-155.
76. Genovese M.C., Kavanaugh A., Weinblatt M.E., et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011, 63:337-345.
77. Weinblatt M.E., Kavanaugh A., Burgos-Vargas R., et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58:3309-3318.
78. Ratanatharathorn V., Carson E., Reynolds C., et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000, 133:275-279.
79. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004, 103:353-359.
80. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
81. Kharfan-Dabaja M.A., Mhaskar A.R., Djulbegovic B., et al. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009, 15:1005-1013.
82. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006, 20:172-173.
83. Sahaf B., Arai S., Otani J., et al. Rituximab provides steroid-sparing therapy in new-onset chronic graft-versus-host disease. Biol Blood Marrow Transplant 2013, 19:S140. [BMT TandemMeeting Abstracts].
84. Arai S., Sahaf B., Narasimhan B., et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012, 119:6145-6154.
85. Kohrt H.E., Turnbull B.B., Heydari K., et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009, 114:1099-1109.
86. Glass B., Hasenkamp J., Gorlitz A., et al. Rituximab for graft-versus-host-disease prophylaxis after allogeneic stem cell transplantation given as treatment of high risk relapse of aggressive lymphoma: results of a randomized phase II study. Blood 2008, 112:1974. [ASH Annual Meeting Abstracts].
87. Dominietto A., Tedone E., Soracco M., et al. Invivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 2012, 47:101-106.